Sign Up to Receive the Latest Trading Tips and News from Prosper

    March 8, 2019

    Earnings Miss Hurts AcelRx

    AcelRx (ACRX) shares slumped in trading today after disappointing earnings results. The company reported $613K in revenue vs. $1.51M consensus estimate. While this was less than half of what was expected, it was not a huge surprise since the company missed revenue estimates by comparable margins over the previous five earnings releases. However, there was […]

    Read Article
    March 5, 2019

    AcelRx Just Waiting For FDA Approval

    AcelRx Pharmaceuticals (ACRX) shares have been up recently as the company awaits an FDA decision on its product Zalviso. Zalviso has already received approval in the European Union, but the FDA previously requested the company to do an additional trial to address certain concerns. AcelRx successfully completed the additional trial and expects the FDA to […]

    Read Article
    February 15, 2019

    AcelRx Is Strong!

    AcelRx Pharmaceuticals (ACRX) shares rose strongly in trading today. The company received initial coverage from Credit Suisse, with an outperform rating and $7 price target. ACRX recently received FDA approval in late 2018 for its powerful opioid DSUVIA. The company insists that it will tightly regulate the distribution and dosage so as to avoid patients […]

    Read Article